Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith Borcoman

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Oncoimmunology|April 4, 2022
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodesLouise Rethacker, Maxime Boy, Valeria Bisio, et al.
International Journal of Molecular Sciences|July 29, 2023
Combined Tumor-Based <i>BRCA1/2</i> and <i>TP53</i> Mutation Testing in Ovarian CancerEdith Borcoman, Elizabeth Santana Dos Santos, Catherine Genestie, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neckKhalil Saleh, Anne Auperin, Nicolas Martin, et al.
Journal of Intensive Medicine|January 28, 2025
Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort studyCamille Windsor, Adrien Joseph, Stephanie Pons, et al.
Cancer Reports (Hoboken, N.J.)|April 18, 2023
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCOREChristophe Le Tourneau, Massimo Ghiani, Maria Chiara Cau, et al.
Drugs in R&D|September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with ImmunotherapyPauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Investigational New Drugs|July 29, 2021
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaGrégoire Marret, Nicolas Isambert, Keyvan Rezai, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II studyJean-Sébastien Frenel, Laurent Mathiot, Claire Cropet, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Oncoimmunology|May 10, 2019
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancerEdith Borcoman, Philippe De La Rochere, Wilfrid Richer, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Oncoimmunology|April 4, 2022
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodesLouise Rethacker, Maxime Boy, Valeria Bisio, et al.
International Journal of Molecular Sciences|July 29, 2023
Combined Tumor-Based <i>BRCA1/2</i> and <i>TP53</i> Mutation Testing in Ovarian CancerEdith Borcoman, Elizabeth Santana Dos Santos, Catherine Genestie, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neckKhalil Saleh, Anne Auperin, Nicolas Martin, et al.
Journal of Intensive Medicine|January 28, 2025
Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort studyCamille Windsor, Adrien Joseph, Stephanie Pons, et al.
Cancer Reports (Hoboken, N.J.)|April 18, 2023
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCOREChristophe Le Tourneau, Massimo Ghiani, Maria Chiara Cau, et al.
Drugs in R&D|September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with ImmunotherapyPauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Investigational New Drugs|July 29, 2021
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaGrégoire Marret, Nicolas Isambert, Keyvan Rezai, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II studyJean-Sébastien Frenel, Laurent Mathiot, Claire Cropet, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Oncoimmunology|May 10, 2019
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancerEdith Borcoman, Philippe De La Rochere, Wilfrid Richer, et al.
Pageof 6